Abbvie submits all-oral hep C application to U.S. regulators; Kala's eye delivery platform spurs $22.5M funding round;

> Abbvie ($ABBV) submitted an FDA application for its all-oral hepatitis C treatment. Story

> Kala Pharmaceuticals, co-founded by Robert Langer, closed a $22.5 million funding round, looking to push forward its ocular treatments that use the company's mucus-penetrating particle delivery platform. Article

> Nitto Denko completed dose escalation of its Phase Ia RNAi-based treatment for fibrosis in the liver and other organs. The siRNA is delivered with a lipid nanoparticle delivery system the company developed in collaboration with Yoshiro Niitsu of Sapporo Medical University. Release

> Ocular Therapeutix will present Phase II data regarding its ReSure Sealant hydrogel with sustained-release dexamethasone at the upcoming American Society of Cataract and Refractive Surgery annual symposium in Boston. Release

> Researchers at the University of Kentucky have developed a method to create heat-resistant nanostructures--including drug delivery structures--using RNA as a building tool. More